Hypercard tablets are used to treat primary hypertrophic cardiomyopathy in cats. This is a condition which results in the heart becoming abnormally large and thickened. If patients are left untreated, the heart muscle gradually declines and the affected cat goes into heart failure. Hypercard acts to slow the heart down and allows the muscle to relax more. Blood vessels are opened up slightly, especially those supplying the heart. This improves the circulation of blood to the heart muscle, and makes it easier to pump blood around the body, reducing the work load on the heart muscle. Life span and quality of life are improved.
Hypercard side effects can include lethargy and anorexia, though these tend to pass in a few days as the patient gets used to the medication. A few cats will show vomiting or constipation, and possibly skin reactions and rashes. In a few cats the heart rate slows down too much and the blood pressure gets too low, so medication has to be stopped.
- Product Price QTY
HyperCard tablets for Cats » 10mg Coated Tablets » Pack of 30Estimated dispatch within 24 working hours. TVP: £15.46 Our price: £8.43 Buy
HyperCard tablets for Cats » 10mg Coated Tablets » Priced per TabletEstimated dispatch within 24 working hours. TVP: £0.52 Our price: £0.28 Buy
- Dosage and administration
- Contraindications, warnings, etc
- Pharmaceutical precautions
- Legal category
- Packaging quantities
- Further information
- Marketing authorisation holder (if different from distributor)
- Marketing authorisation number
- GTIN (Global Trade Item No)
1 tablet contains: Active substance:
Diltiazem 9.20 mg (equivalent to 10 mg of Diltiazem hydrochloride)
Excipients: Tartrazine (E102) 0.11 mg, titanium dioxide (E171) 1.1 mg. Also contains sodium methyl hydroxybenzoate (E219), microcrystalline cellulose, lactose monohydrate, maize starch, magnesium stearate, polyethylene glycol 4000, povidone (K30), food grade shellac, isopropanol, sucrose, purified water.
A yellow coated biconvex tablet.
For the therapeutic treatment of feline primary hypertrophic cardiomyopathy.
Dosage and administration
For oral administration.
1 tablet per cat (weighing 3.0-6.25 kg body weight) every eight hours (equivalent to 1.6-3.3 mg diltiazem hydrochloride per kg every 8 hours).
Treatment should be given for the life of the animal.
Contraindications, warnings, etc
Do not use in animals suffering from AV block (2nd or 3rd), hypotension or sick sinus syndrome.
Diltiazem should not be given to animals suffering from hepatic disease.
Do not use in animals suffering from renal disease.
Do not use in cats less than 12 months old.
Do not use in cats weighing less than 3 kg.
Do not use in animals that are hypersensitive to diltiazem.
Do not use in cats with severe bradycardia or arterial hypotension.
Do not use in conjunction with beta-blockers, digitalis or digoxin.
Do not use in pregnant or lactating females.
Special precautions for use in animals: Hepatic failure may increase the plasma concentration of diltiazem.
Monitor glucose levels carefully in diabetic animals.
Use with caution in cats suffering from congestive heart failure.
Cats with possible pre-existing thyroid problems or hyperthyroidism should be treated for this first and then be reassessed, prior to commencing treatment with diltiazem.
Clinical examination to assess the effectiveness of treatment should be performed after 8 weeks.
Cardiac rate should be monitored prior to treatment commencing and at every follow up visit.
Special precautions for the person administering the veterinary medicinal product to animals: Wash hands after use as tartrazine in the colour coating may cause allergic reaction in people who are susceptible.
In case of accidental ingestion, seek medical advice immediately and show the data sheet to the physician.
Do not break tablets.
Adverse reactions: Some lethargy can occur at the beginning of treatment.
Diltiazem may cause gastrointestinal problems, e.g. constipation, vomiting and anorexia.
Rashes, skin reactions and erythema are potential side effects of diltiazem.
Bradycardia, dyspnoea, hypotension and conduction abnormalities may occasionally occur. In such cases treatment should be suspended.
Use during pregnancy and lactation: Do not use in pregnant or lactating females. Studies of laboratory animals have shown evidence of teratogenic and embryotoxic effects.
Interactions: Use with caution in conjunction with other calcium channel blockers, anticonvulsant drugs, immunosuppressant drugs, lithium, neuromuscular blocking agents and aminoglycoside antibiotics.
Concurrent use with cimetidine or any other histamine 2 receptor antagonists may cause an increase in plasma diltiazem concentrations.
Gaseous anaesthetics such as halothane, isoflurane or enflurane have synergistic or additive effects with diltiazem, which may lead to hypotension, depressed myocardial contractile function, slow junctional rhythm and AV block. Therefore, animals treated with Hypercard 10 mg and undergoing gaseous anaesthesia should be monitored closely.
Overdose: Carry out gastric lavage and dose with activated charcoal.
For bradycardia and heart block, treat with normal saline infusion and vasopressors (atropine, dopamine or isoprenaline).
Observations in humans have indicated that treatment with calcium may be useful in treating toxicity from calcium channel blocker overdose.
Do not store above 25°C. Keep the blister strips in the outer carton. Do not use after the expiry date which is stated on the carton and blister after EXP.
Shelf life of the veterinary medicinal product as packaged for sale: 30 months.
Disposal: Any unused veterinary medical product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Tablets are located in a pre-formed low density polyethylene base containing 10 tablets and sealed with PC 100 laminate comprising of low density polyethylene and aluminium foil. Once sealed, 3 blisters of 10 tablets (30 tablets) are placed in a cardboard box.
For animal treatment only. To be supplied only on veterinary prescription. Keep out of the reach and sight of children.
Manufacturer: Dales Pharmaceuticals, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW.
Date of last review: September 2010
Marketing authorisation holder (if different from distributor)
Dechra Limited, Dechra House, Jamage Industrial Estate, Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW.
Marketing authorisation number
GTIN (Global Trade Item No)
Hypercard 10 mg Coated Tablets for Cats
Need help or advice? Contact us:
- Freephone: 0800 084 2608
- Mon - Fri: 8:30am - 7:00pm
- Sat: 10:00am - 3:00pm
- Email: firstname.lastname@example.org
All prices include VAT where applicable.
No Reviews For HyperCard tablets for Cats
Have you tried HyperCard tablets for Cats? Be the first to write a review!
There are currently no questions for HyperCard tablets for Cats
Ask your own question about HyperCard tablets for Cats
Thank you for your question regarding HyperCard tablets for Cats, you will receive an email when a member of our team provides an answer.